ADVFN Logo ADVFN

We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now

Toplists

It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Sign Up

Already a member? Sign in

Interactive Brokers

Interactive Brokers
Market Data
News
Trading Tools
Markets
Discover

Hot Features

Follow Feed

Connect with traders and investors in our Follow Feed community.

Options Flow

Explore comprehensive options data and use advanced filters with Options Flow.

Monitor

Organize and monitor your stock and asset watchlist with Monitor.
Sign In Premium IconPremium Help Menu
S&P 500
5,187.70
0.13%
US Tech 100
17,611.20
-0.01%
Dow Jones
38,884.26
0.08%
Brent Oil
82.235
-0.76%
Bitcoin
62,253.66
-0.13%
Registration Strip Icon for smarter Trade smarter, not harder: Unleash your inner pro with our toolkit and live discussions.
Get Started
  1. Home
  2. Investing
  3. Stocks
  4. USA
  5. NASDAQ
  6. Revance Therapeutics Inc (RVNC)

  7. Revance Therapeutics Inc (RVNC) News

Revance Therapeutics Inc

Revance Therapeutics Inc (RVNC)

NASDAQ
4.38
0.28
(6.83%)
Closed May 07 4:00PM
Delayed by 15 minutes
4.38
0.00
( 0.00% )
Pre Market: 5:40AM
Delayed by 15 minutes

Professional-Grade Tools, for Individual Investors.

Premium

RVNC News

Official News Only

Form 8-K - Current report
Edgar (US Regulatory)
February 13 2024
RVNC (6.83%)

Form 8-K - Current report
Edgar (US Regulatory)
February 06 2024
RVNC (6.83%)

Form 4 - Statement of changes in beneficial ownership of securities
Edgar (US Regulatory)
February 02 2024
RVNC (6.83%)

Form 4 - Statement of changes in beneficial ownership of securities
Edgar (US Regulatory)
February 02 2024
RVNC (6.83%)

Form 4 - Statement of changes in beneficial ownership of securities
Edgar (US Regulatory)
February 02 2024
RVNC (6.83%)

Form 8-K - Current report
Edgar (US Regulatory)
January 08 2024
RVNC (6.83%)

RVNC Discussion

View Posts
PioneerUniverse8 PioneerUniverse8 3 minutes ago
couple other tidbits i was able to gather:

- according to this dermatologist, her patients are generally willing to switch and try Daxxify
- this dermatologist's assistant is using Daxxify exclusively and is very happy about it

Still too early to know if my wife will like it. She did Botox couple of times before, so there is some basis for comparison.
👍️0
PioneerUniverse8 PioneerUniverse8 14 minutes ago
Wife did Daxxi yesterday (and bit of RHA fillers). The dermatologist said she should expect 9 moths duration for 11 lines. I thought that was perhaps a bit too optimistic, but lets see. In regards to slowdown that Botox reported, I think a large part of it is just a genuine market loss to competitors. I expect that Revance will also have favorable QoQ differential.
👍️0
boraborak38 boraborak38 7 hours ago
That’s about $2 million more in revenue than I thought. Don’t seem to be following the Botox slowdown that Abbvie reported :)
👍️ 1
boraborak38 boraborak38 7 hours ago
Not sure why that’s an issue. It’s been addressed so many times before. That was a fantastic report.
😂 1 🤡 1
DewDiligence DewDiligence 13 hours ago
Number of comments and questions about double-dose Jeuveau during EOLS 1Q24 CC today: zero.
👍️ 6 😂 1 🤣 1
soma2022 soma2022 14 hours ago
Evolus Q1 2024 Earnings:
Estim Revenue: $57M, Real: $59M (beat by $2M - 3.5%), down 1.7% from Q4 2023 Rev: $60M. (Botox down 14% QoQ)
cash burn: $10.6M
interest on debt: $4.7M
cash: $97M (they raised $47M in secondary March 2024)
debt: $120M (@14.5%)
year on year quarterly revenue growth: 42% (Botox down 5% y/y)
Jeuveau ordering Accts since 2019 launch: 13K
New accts: 700

Q1 2024 Botox Cosmetic : $389M (-14% QoQ, -5% YoY)
👍️ 1
Emannow Emannow 15 hours ago
RVNC % sales will mirror or most likely beat Evolus % sales numbers for Q1. Additionally, there should be a several million dollar backorder for CD Daxi which should ship on 5/10/2024

Evolus Reports First Quarter 2024 Results and Provides Business Update
Q1 2024 Net Revenue of $59.3 Million, Up 42% from Q1 2023
Non-GAAP Loss from Operations of $0.9 Million, on Track to Non-GAAP Profitability1 in Q4 2024 and Full Year 2025
Reaffirms Full-Year 2024 Net Revenue Guidance of $255 Million to $265 Million, Representing a 31% Growth Rate at the Top End
Remains on Track to Achieve Projected Total Net Revenue Goal of At Least $700 Million by 2028
👍️ 2
go seek go seek 15 hours ago
RVNC was and is undervalued / oversold…
👍️0
vinmantoo vinmantoo 16 hours ago
RVNC is up over $1 since its low of $3.29 in late April. Does that mean the market wrong before and is just beginning to correct itself?
👍️0
go seek go seek 1 day ago
LETYBO… thanks for the information. I believe Mark Foley commented on this late in his 12 March webcast w Barclays. He said that he expected DAXXIFY would compete well against what he considered to be another ‘me too’ Botox toxin… saying DAXXIFY was unique, differentiated by innovation (use of peptide). Best2u.
👍️ 1
TimelessGoblin26 TimelessGoblin26 1 day ago
https://academic.oup.com/asj/article/42/6/677/6517357?login=false

Here is the clinical trial results. Seems OK, fast onset. But I don't see strong evidence supporting "longer lasting" claim.
👍️ 2
alertmeipp alertmeipp 2 days ago
I guess many are not happy with Angus and Foley, especially Foley's compensation.



1. Each of the Class I nominees of the Company’s Board of Directors (the “Board”) were elected to hold office until the Company’s 2027 annual meeting of stockholders, as follows: Angus Russell: 46,115,633 shares of common stock voted for and 23,876,260 shares of common stock withheld; Julian Gangolli: 64,257,114 shares of common stock voted for and 5,734,779 shares of common stock withheld; and Olivia Ware: 52,294,395 shares of common stock voted for and 17,697,498 shares of common stock withheld. There were a total of 19,398,055 broker non-votes for the election of the Class I nominees. The terms of office of the Class II directors, Mark J. Foley and Christian W. Nolet, continue until the Company’s 2025 annual meeting of stockholders. The terms of office of the Class III directors, Jill Beraud, Carey O'Connor Kolaja and Dr. Vlad Coric, continue until the Company’s 2026 annual meeting of stockholders.

2. The stockholders ratified the selection by the Audit Committee of PricewaterhouseCoopers LLP as the independent registered public accounting firm of the Company for its fiscal year ending December 31, 2024, as follows: 88,457,575 shares of common stock voted for, 849,475 shares of common stock voted against, 82,898 shares of common stock abstaining and no broker non-votes.

3. The stockholders approved, on an advisory basis, the compensation of the Company’s named executive officers as disclosed in the 2024 Proxy Statement, as follows: 51,554,931 shares of common stock voted for, 18,083,102 shares of common stock voted against, 353,860 shares of common stock abstaining and 19,398,055 broker non-votes.
👍️ 3
go seek go seek 5 days ago
Any thoughts on LETYBO which should be in the US market later this year?
👍️0
vinmantoo vinmantoo 5 days ago
AEON’s lead indication had previously been cervical dystonia, but AEON backed off from CD after RVNC reported stellar data in that indication.

I like the way that sounds.
👍️0
DewDiligence DewDiligence 5 days ago
AEON—(-53%)—reports failed phase-2 in migraine prevention:

https://finance.yahoo.com/news/aeon-biopharma-announces-preliminary-top-110000987.html AEON Biopharma…today announced that the preliminary top-line results from its planned interim analysis of the Phase 2 trial with ABP-450 in the preventive treatment for chronic migraine did not meet the primary endpoint. This is AEON’s second phase-2 failure in migraine, having whiffed in a prior phase-2 for treatment (rather than prevention) of episodic migraine (#msg-173058579).

AEON’s ABP-450 is the exact same drug as EOLS’ Jeuveau, sourced from Korea's Daewoong.

AEON’s lead indication had previously been cervical dystonia, but AEON backed off from CD after RVNC reported stellar data in that indication.

Please see #msg-172274907 for related info.
👍️ 6
alertmeipp alertmeipp 5 days ago
Finally an ad that looks decent

The power move one was lame
👍️ 2
vinmantoo vinmantoo 5 days ago
$3.77
How long before a Big Pharma Co. J&J decides to purchase RVNC to add to their Mentor Breast Implant Biz like Allergan?

What makes you think RVNC would accept a buyout at this absurdly low price?
👍️ 1
go seek go seek 5 days ago
New Daxxi ad…
https://www.instagram.com/reel/C6ekJTlPozL/?igsh=cDlhdHNvZzh3ajRz

Ad liked by one of the top dermatologists in NYC… Dr. Ellen Marmur
https://www.instagram.com/reel/C3-pJf6r6t-/?igsh=MTQyN2U5a3N4Zjl6eg==

Read comments…
👍️ 1
go seek go seek 5 days ago
Vote details to be published on or about 5 May.
👍️ 1
AXRX4952 AXRX4952 5 days ago
$3.77
How long before a Big Pharma Co. J&J decides to purchase RVNC to add to their Mentor Breast Implant Biz like Allergan? Or Pfizer who tried to buy Allegan, Sientra? You can't be successful if your salesforce is leaving left and right. Retention is a big issue there. The innerworkings of this company is a huge mess.
👍️ 1 🤥 1
AXRX4952 AXRX4952 5 days ago
Teoxane RHA was world wide 5 years BEFORE RVNC got it launched in the USA and all RVNC has to do was copy paste their marketing concepts and follow the other global distributors - who have had Teoxane portfolio for 20 years.
Daxxi is their own product and they have had YEARS to come up with a successful marketing plan and execute it. They failed miserably. It's like you had ONE job and you failed.
👍️ 3 👎️ 3
alertmeipp alertmeipp 5 days ago
Anyone know the voting result %?
🤔 1
PioneerUniverse8 PioneerUniverse8 5 days ago
Them not answering questions (even though the questions were not related to the 3 items that were being voted on) is a total dick move. Ultimately it shows a disrespect for minority shareholders.
👍️ 3 😢 1
randychub randychub 6 days ago
Per rumor? I thought Rvnc stated that in the past
👍️0
Emannow Emannow 6 days ago
Per a rumor, Daxi CD is to be officially launched on May 9th.
👍️ 1 😍 1
soma2022 soma2022 6 days ago
Evolus reports May 7th after close
Estim Rev: $57M, loss of 8 cents/share.
Q4 2023 Rev: $60M COGS: $19M
Key items: cash burn, interest on debt, cash balance, year on year revenue growth, QoQ revenue change.

Revance reports May 9th after close
Q4 2023: RHA: $34.5M, Daxi: $24M
Key items: RHA/Daxi Revenue growth YoY and QoQ, cash burn, cash balance, GMs, Daxxify vial unit growth QoQ, and CD launch progress and expense management.

Compare to Abbvie's Botox/filler sales for same quarters.
👍️ 2 🤝 1
Emannow Emannow 6 days ago


Institutions have bought back into RVNC

Capital Research now owns 13.83 million shares and is the largest share holder
👍️ 1
DewDiligence DewDiligence 6 days ago
We dont even know when earnings day is.May 9:

https://investors.revance.com/investors/Press-Releases/news-details/2024/Revance-to-Release-First-Quarter-2024-Financial-Results-on-Thursday-May-9-2024/default.aspx
👍️ 3
Tomdontworry Tomdontworry 6 days ago
I posted 2 questions in the chat box as well… i expected more from the investor day. We dont even know when earnings day is..
👍️0
go seek go seek 6 days ago
Gotcha… who’s the Brittany Spaniel in your profile photo? Thanks. We’ll all feel better about Revance when the share price steadily moves higher.
👍️ 1
Emannow Emannow 6 days ago
Yes, I asked the question, “could you explain why there is no communication with Wall Street on your company “.

They simply did not answer any questions!
👍️ 2
go seek go seek 6 days ago
…did not take any questions. Did you ask a question? I think they did not want to ‘get into the weeds’ in this shareholder meeting. Just my guess. As you know, we were told that there were no questions. Best to you.
👍️0
Emannow Emannow 6 days ago
I listened to the Shareholders call! Angus Russell ran the call and did not take any questions! Why would Russell answer questions about his many bad decisions! Angus has absolutely no idea what he is doing in aesthetics! The guy is clueless which is why the SP is down 90% and 95% of the corporate staff has been let go so they can pay their electric bill! Angus Russell should be removed!
👍️ 2
biotech_researcher biotech_researcher 6 days ago
Bad decision. There is a lot going on, and they didn’t what to share?
👍️0
go seek go seek 6 days ago
Alert… they just did the vote. No discussion of company operations. Nada…
👍️ 3
alertmeipp alertmeipp 6 days ago
Annual meeting - anyone attended or listened to the call? Any notes? TIA
👍️0
go seek go seek 1 week ago
Not sure why…
IMO it is impossible to determine the whys and wherefores of price actions or trends thereto… The market is not efficient. Bottomline it is fear vs greed and uncertainty vs clarity. Revance has exceptional products in very large and growing markets. Over time, as confidence and sales in these products grow… uncertainty will abate and the stock price should rise.
👍️ 2
Emannow Emannow 1 week ago
Not sure why whoever is shorting RVNC is working so hard! 54% of trades yesterday and 56% of trades today were shorts. Seems someone or some entity is determined at all costs to keep the SP down.
👍️ 1
Emannow Emannow 1 week ago


Starting to see injectors offering Daxi at a Fair Price! This will grow sales!!
👍️ 5 💯 2
go seek go seek 1 week ago
You are cordially invited to attend the Annual Meeting of Stockholders of REVANCE THERAPEUTICS, INC. The meeting will be held virtually on Wednesday, May 1, 2024 at 10:00 a.m. Central Time via live audio-only webcast at www.virtualshareholdermeeting.com/RVNC2024 .
👍️ 1
mouton29 mouton29 1 week ago
You are harping on the low end of the range, 30 percent, when he is reporting 30 to 100 percent increases. That’s like focusing on the Revance reported results and saying they report 0 percent increase, when they in fact report a range corresponding to something like 0 to 2x with a median of 1x.

I do take your point that other steps could be taken to optimize results and it doesn’t seem like Revance provides a lot of guidance or effort there, so that there’s a fair bit of experimentation and in some cases floundering by some injectors.
👍️ 4
iwfal iwfal 1 week ago
That's not bad and does it really vary materially from the Revance results, given the reduced dose and he is reporting results between 30% and 100% longer.

Sure, agree '30% longer' is in line with 'reduced dose'. But the point stands that the 'feeling too heavy', which was why he reduced the dose doesn't. It seems pretty likely to indicate better optimization is possible. And 30% longer vs, say 65% longer... matters significantly when trying to get word-of-mouth to work. Eg 30% is likely only a little above the noise floor for an individual patient (eg session to session variability), whereas 65% is likely way above it.
👍️ 1
mouton29 mouton29 1 week ago
only mildly increase in duration

What he said was, at the 1.65 x dose,

it lasted significantly longer than Botox and what we saw at that 1.65 to 1 is at least 30% longer duration and as much as double the duration in that range.

That's not bad and does it really vary materially from the Revance results, given the reduced dose and he is reporting results between 30% and 100% longer. We don't know what median that translates to but clearly it's north of 30% and likely somewhere in the 50% range. And likely he is reporting the injector evaluation, not the Revance better of the injector and patient evaluation (which significantly skews the median upward).
👍️ 1
biotech_researcher biotech_researcher 1 week ago
It might be that the millennials steer this more than the baby boomers now
👍️ 1
iwfal iwfal 1 week ago
Interesting in that he’s playing with dose, but weirdly unclear on *how* he’s playing w dose (eg further dilution or just less volume injected). My guess is that in order to really unlock Daxxy benefits (longer lasting, cheaper, few AE) you need to play with at least 2 of 3 things: injection pattern, dilution and dose per injection. And he’s only doing one, hence his fairly limited endorsement (too much is too heavy, only mildly increase in duration).
👍️ 2
go seek go seek 1 week ago
New Daxxi Provider and what sets Daxi apart from other neuromodulators…
https://www.instagram.com/reel/C4qvLGJRcGf/?igsh=MTMzMmQ3MnFtNjRreA==
👍️ 1
edcoolidge edcoolidge 1 week ago
Many of the practices offering Daxxify do heavily market that it is vegan. It's a strong selling point and Revance should definitely lean into it. However I think the use of the word "safe" or any allusion to these types of incidents is a very bad idea.
👍️ 1 🤡 1
edcoolidge edcoolidge 1 week ago
Where are all the "market is never wrong" folks today. 🤣
👍️ 1 😉 1 🤡 1
go seek go seek 1 week ago
Daxxi Dosage Experience
https://www.instagram.com/reel/C5ygX2BRxYx/?igsh=eXY4dnVnMDg4NGV5
👍️ 1
Monksdream Monksdream 1 week ago
RVNC under $5
👍️0

Your Recent History

NASDAQ
RVNC
Revance Therapeutics
Delayed Upgrade Clock
ADVFN Logo

United States
Company
Business
Popular
Get The App

Support: 1-888-992-3836 | support@advfn.com

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

© 2024 ADVFN PLC - All Rights Reserved